子宫内膜癌ProMisE分子分组的组织病理学特征:系统综述与Meta分析
该系统综述与Meta分析旨在描述ProMisE四个分子分组(POLE突变型、MMR缺陷型、p53异常型、p53野生型)在组织学分级、组织类型、LVSI、深肌层浸润、淋巴结受累及ESMO风险分类方面的组织病理学特征。共纳入4项研究1171例患者,其中3项研究912例纳入Meta分析,汇总了各分组中每种组织病理学特征的合并患病率。结论提示许多患者目前存在治疗不足或过度治疗(尤其是POLE突变型和MMR缺陷型组)。
要点
- ProMisE分组包括POLE突变型、MMR缺陷型、p53异常型和p53野生型四组。
- Meta分析纳入3项研究912例患者,汇总各分组组织病理学特征的合并患病率。
- 组织病理学特征描述提示POLE突变型和MMR缺陷型组可能存在治疗不足或过度治疗。
核心结论
- ProMisE分组的组织病理学特征描述提示许多患者目前存在治疗不足或过度治疗,尤其在POLE突变型和MMR缺陷型组。
研究设计与样本
- 系统综述与Meta分析,检索7个电子数据库自建库至2019年5月。
- 系统综述纳入4项研究共1171例患者,其中3项研究912例患者纳入Meta分析。
主要发现
- 计算了每个ProMisE分组中EC各组织病理学特征(组织学分级G3 vs G1-2、组织类型、LVSI、深肌层浸润>50%、淋巴结受累、ESMO风险分类)的合并患病率。
临床怎么用
- 组织病理学特征描述有助于理解ProMisE分子分类如何改变当前患者管理,减少过度治疗和治疗不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) development, endometrial cancer (EC) may be reclassified in four novel prognostic groups: POLE-mutated (POLE-mt), mismatch-repair-deficient (MMR-d), p53-abnormal (p53abn), p53-wild-type (p53wt). However, histopathological characteristics of each ProMisE group are still undefined. Such characterization may be useful to understand how this novel molecular classifier may change the current patient management, reducing over- and undertreatment. AIM: To provide a histopathological characterization of ProMisE groups of EC, in terms of histological grade (G3 vs G1-2), histotype, lymphovascular space invasion (LVSI), deep myometrial invasion (>50%), lymph node involvement, and European Society for Medical Oncology (ESMO) risk category. MATERIALS AND METHODS: A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to May 2019, for studies that reported histopathological characteristics of each ProMisE group. Pooled prevalence of each histopathological characteristic of EC in each ProMisE group was calculated. RESULTS: Four studies with 1171 patients were included in the systematic review, out of which three studies with 912 patients were included in the meta-analysis. Pooled prevalence estimates were: CONCLUSIONS: The histopathological characterization of the ProMisE groups suggests that many patients are currently undertreated or overtreated (especially in the POLE-mt and MMR-d groups).
引用
- Raffone A, Travaglino A, Mascolo M, et al. Histopathological characterization of ProMisE molecular groups of endometrial cancer. Gynecol Oncol. 2020. PMID: 31932106. doi:10.1016/j.ygyno.2020.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。